Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Omri Bodenheimer"'
Autor:
Ofra Amir, Yair Goldberg, Micha Mandel, Yinon M. Bar-On, Omri Bodenheimer, Laurence Freedman, Sharon Alroy-Preis, Nachman Ash, Amit Huppert, Ron Milo
Publikováno v:
Communications Biology, Vol 6, Iss 1, Pp 1-7 (2023)
Patient data from the Israeli Ministry of Health demonstrates that a 3rd dose of BNT162b2 is effective in reducing Omicron BA.1/BA.2 severe disease and does not wane over the seven month study period as well as that a fourth dose further improves the
Externí odkaz:
https://doaj.org/article/b079a1be90224e5b949b7ead641245fe
Autor:
Ofra Amir, Yair Goldberg, Micha Mandel, Yinon M. Bar-On, Omri Bodenheimer, Nachman Ash, Sharon Alroy-Preis, Amit Huppert, Ron Milo
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-5 (2022)
This study compares SARS-CoV-2 infection rates following a recent second or third dose of the BNT162b2 (Pfizer/BioNTech) vaccine. They use data from Israel for 12–14 year olds (second dose) and 16–18 year olds (third dose), and find a 3.7-fold hi
Externí odkaz:
https://doaj.org/article/5e798c9a54634be492c4de72f5ceb557
Autor:
Ofra, Amir, Yair, Goldberg, Micha, Mandel, Yinon M, Bar-On, Omri, Bodenheimer, Laurence, Freedman, Nachman, Ash, Sharon, Alroy-Preis, Amit, Huppert, Ron, Milo
Publikováno v:
The Lancet Infectious Diseases. 23:67-73
The BNT162b2 (Pfizer-BioNTech) two-dose vaccine regiment for children and the BNT162b2 third dose for adolescents were approved shortly before the SARS-CoV-2 omicron (B.1.1.529) outbreak in Israel. We aimed to estimate the effects of these vaccines o
Autor:
Khitam Muhsen, Nimrod Maimon, Amiel Yaron Mizrahi, Boris Boltyansky, Omri Bodenheimer, Zafrira Hillel Diamant, Lea Gaon, Dani Cohen, Ron Dagan
Publikováno v:
JAMA Intern Med
IMPORTANCE: The administration of a fourth BNT162b2 COVID-19 vaccine dose was approved in Israel in December 2021 for individuals 60 years or older who were vaccinated with a third dose 4 months previously or earlier to control the substantial surge
Autor:
Ofra Amir, Yair Goldberg, Micha Mandel, Yinon M Bar-On, Laurence S Freedman, Omri Bodenheimer, Amit Huppert, Ron Milo
Publikováno v:
International Journal of Epidemiology.
Autor:
Yair Goldberg, Micha Mandel, Yinon M. Bar-On, Omri Bodenheimer, Laurence S. Freedman, Nachman Ash, Sharon Alroy-Preis, Amit Huppert, Ron Milo
Publikováno v:
New England Journal of Medicine. 386:2201-2212
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provides natural immunity against reinfection. Recent studies have shown waning of the immunity provided by the BNT162b2 vaccine. The time course of natural and hybrid immuni
Autor:
Yinon M. Bar-On, Micha Mandel, Omri Bodenheimer, Laurence Freedman, Barak Mizrahi, Yair Goldberg, Sharon Alroy-Preis, Nachman Ash, Amit Huppert, Nir Kalkstein, Ron Milo
Publikováno v:
New England Journal of Medicine. 385:1393-1400
Background On July 30, 2021, the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer-BioNTech) was approved in Israel for persons who were 60 years of age or older and who had received a second dose of vaccine at le
Autor:
Ofra Amir, Yair Goldberg, Micha Mandel, Yinon M. Bar-On, Omri Bodenheimer, Laurence Freedman, Nachman Ash, Sharon Alroy-Preis, Amit Huppert, Ron Milo
BACKGROUNDThe BNT162b2 (Pfizer-BioNTech) 2-dose vaccine for children and the BNT162b2 3rd dose for adolescents were approved shortly before the Omicron outbreak in Israel. The effects of these vaccines on the rates of Omicron confirmed infection are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa3088e926e5740a38a1e8dac679c638
https://doi.org/10.1101/2022.05.22.22275323
https://doi.org/10.1101/2022.05.22.22275323
Autor:
Ofra Amir, Yair Goldberg, Micha Mandel, Yinon M. Bar-On, Omri Bodenheimer, Laurence Freedman, Sharon Alroy-Preis, Nachman Ash, Amit Huppert, Ron Milo
Following a rise in cases due to the delta variant and evidence of waning immunity after 2 doses of the BNT162b2 vaccine, Israel began administering a third BNT162b2 dose (booster) in July 2021. Recent studies showed that the 3rd dose provides a much
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90d2a899c58a7fe820f01c706150e29d
https://doi.org/10.1101/2022.05.04.22274647
https://doi.org/10.1101/2022.05.04.22274647
Autor:
Yinon M. Bar-On, Yair Goldberg, Micha Mandel, Omri Bodenheimer, Ofra Amir, Laurence Freedman, Sharon Alroy-Preis, Nachman Ash, Amit Huppert, Ron Milo
BACKGROUNDOn January 2, 2022, Israel began administering a fourth dose of BNT162b2 vaccine (Pfizer-BioNTech) to people aged over 60 years and at-risk populations, who had received a third dose of vaccine at least 4 months earlier. The effect of the f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a695ca3de7ad120f35a38c4c341828b0
https://doi.org/10.1101/2022.02.01.22270232
https://doi.org/10.1101/2022.02.01.22270232